BPC-157
Tissue-repair peptide
Research overview
A 15-amino-acid peptide widely studied in models of connective-tissue, tendon and gastric-mucosa repair.
Descriptions reference published research areas for laboratory context only and are not claims of efficacy, safety, or intended use in humans or animals.
- Price
- $95 CAD
- Purity
- ≥99.2% (HPLC)
- Presentation
- 10 mg lyophilized vial
Order / inquire about BPC-157
Email our research desk for availability, batch Certificates of Analysis, and account setup. We respond to verified research inquiries from Canada only.
Verified Canadian research inquiries only · 18+
For laboratory research use only — not for human or veterinary use
BPC-157 is a chemical reference material sold strictly for in-vitro laboratory research by qualified professionals. It is not a drug, food, cosmetic, or natural health product; it has not been evaluated or approved by Health Canada; and it must never be ingested, injected, or applied to humans or animals. Sold in Canada only, to purchasers 18+. See our Research Use Policy.
Research encyclopedia
Everything the literature has studied.
For laboratory research use only — not for human or veterinary use. The content below summarizes published research context only. It is not medical advice, makes no therapeutic claims, and describes no intended use in humans or animals. These materials have not been evaluated or approved by Health Canada.
What it is
Synthetic pentadecapeptide (15 amino acids) corresponding to a partial sequence of the 'Body Protection Compound' (BPC) originally identified in human gastric juice. Widely studied in preclinical models for cytoprotective and tissue-repair effects, and notable for unusual stability in acidic gastric juice (>24 h).
Mechanism of action
Modulates angiogenesis via VEGFR2 activation with downstream FAK-paxillin signaling, the Egr-1 pathway, and the Akt/PI3K cell-survival cascade. Activates endothelial nitric oxide synthase (eNOS), promoting vasodilation and blood flow toward damaged tissue, and interacts with the nitric-oxide (NO) system and the dopaminergic, serotonergic, and GABAergic systems in nervous-tissue models. Upregulates growth-factor receptors (e.g., EGR-1, NAB2) supporting fibroblast function and collagen organization.
Research areas
- Repair of tendon, ligament, and muscle
- Protection and repair of the gastrointestinal mucosa
- Angiogenesis and vascular homeostasis
- Nervous system injury models
Studied effects in research models
- Promotion of angiogenesis and blood flow
- Stimulation of type 1 collagen synthesis
- Gastrointestinal cytoprotective effects
- Modulation of the nitric-oxide system in vascular models
Effects listed describe observations reported in laboratory or animal research models only — not outcomes claimed for humans or animals.
Biomarkers tracked in related research
Discovery & background
Described by the group of Predrag Sikirić at the University of Zagreb, Croatia, in the early 1990s. It is a stable fragment (residues 1-15) of a larger protein found in human gastric juice, and its exceptional resistance to hydrolysis in acid gastric juice (>24 h) distinguishes it from most peptides. A first-in-human intravenous safety study (up to ~20 mg) reported short-term tolerability, but was not designed to detect tumor promotion or chronic effects.
Considerations & limitations
Research use only. Not approved by Health Canada, the FDA, or other regulators for human or veterinary use. Evidence is almost exclusively preclinical (rodent/in vitro); no large human clinical trials exist. Prohibited by WADA (S0, non-approved substances) in sport. The angiogenic mechanism raises a theoretical concern about supporting tumor growth, so it is considered inappropriate in the context of active malignancy; no pregnancy/lactation safety data. Require a Certificate of Analysis (HPLC purity ideally ≥98%, identity by mass spectrometry, sterility/endotoxin testing).
References
- [1]Sikiric et al., 2020 — Curr Neuropharmacol; PMID: 32175841
- [2]Chang et al., 2011 (tendon fibroblast outgrowth) — J Appl Physiol; PMID: 21030674
- [3]Seiwerth et al., 2018 (BPC 157 and angiogenesis) — Curr Pharm Des; PMID: 29769016
- [4]Gwyer, Wragg & Wilson, 2019 (review) — Cell Tissue Res; DOI: 10.1007/s00441-019-03016-8